TITLE

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature

PUB. DATE
January 2011
SOURCE
Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
The article presents a case study of a 47-year-old, Caucasian woman who developed Buffalo Hump at the time of antiretroviral therapy which includes raltegravir and unboosted atazanavir for treating Human Immunodeficiency virus (HIV)-1 infection. It informs that the diagnosis revealed that the side effect was developed after changing antiretroviral therapy to raltegravir and unboosted atazanavir. It also informs that Buffalo Hump is commonly occur in HIV-1 infected individuals.
ACCESSION #
65144696

 

Related Articles

  • The Observatory. HIV/AIDS.  // MLO: Medical Laboratory Observer;Jan2011, Vol. 43 Issue 1, p6 

    The article offers news briefs related to human immunodeficiency virus (HIV) infection which includes the report by Adult Industry Medical (AIM) Healthcare Foundation clinic, where the performer of porn films was tested HIV-positive, states that other adult film actors or his personal contacts...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • Hope and hype.  // Network Magazine of the Canadian Women's Health Network;Winter1998/1999, Vol. 2 Issue 1, p3 

    Relates how the author decided to go on combination therapy to combat HIV-related symptoms. Author's initial refusal to take any AIDS drugs; Details of how the author reached the decision to try a combination of AIDS drugs; Author's daily medication routine; Effects of the combination therapy.

  • Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Machado, E. S.; Hofer, C. B.; Costa, T. T.; Nogueira, S. A.; Oliveira, R. H.; Abreu, T. F.; Evangelista, L. A.; Farias, I. F. A.; Mercadante, R. T. C.; Garcia, M. F. L.; Neves, R. C.; Costa, V. M.; Lambert, J. S. // Sexually Transmitted Infections;Apr2009, Vol. 85 Issue 2, p82 

    Objective: The potential adverse effects of antiretroviral drugs during pregnancy are discrepant and few studies, mostly from Europe, have provided information about pregnancy outcomes of those already on treatment at conception. The aim of this study was to investigate the impact...

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

  • Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)—Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens. Domingo, Pere; Cabeza, Maria Carmen; Pruvost, Alain; Salazar, Juliana; del Mar Gutierrez, Maria; Mateo, Maria Gracia; Domingo, Joan C.; Fernandez, Irene; Villarroya, Francesc; Muñoz, Jessica; Vidal, Francesc; Baiget, Montserrat // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p1033 

    Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)- associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels...

  • Ribavirin‑free Treatment May Soon be a Reality. Al‑Judaibi, Bandar // Saudi Journal of Gastroenterology;Jul/Aug2015, Vol. 21 Issue 4, p260 

    A letter to the editor is presented in response to the article "SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection," by A. A. Alghamdi and colleagues in the 2015 issue.

  • Emtricitabine/Tenofovir Disoproxil Fumarate: A Viewpoint by Daniel Podzamczer. Podzamczer, Daniel // Drugs;2004, Vol. 64 Issue 18, p2083 

    Emtricitabine/tenofovir disoproxil fumarate combination has many advantages as a highly active antiretroviral therapy (HAART) for HIV infection. Both compounds are potent and well tolerated by patients. The compounds have been proven effective as part of different HAART regimens in clinical...

  • Emtricitabine/Tenofovir Disoproxil Fumarate. Dando, Toni M.; Wagstaff, Antona J. // Drugs;2004, Vol. 64 Issue 18, p2075 

    â–´ The nucleoside analogue reverse transcriptase inhibitor (RTI) emtricitabine and the nucleotide analogue RTI tenofovir disoproxil fumarate (tenofovir DF) have each shown antiviral activity against a number of HIV clinical isolates and cell lines. â–´ HIV variants with reduced...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics